Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the acute treatment of migraine attacks, with or without aura, and is administered by a single subcutaneous dose as directed by a healthcare professional.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet EU regulatory standards, providing reliable global distribution, and supporting procurement teams with regulatory documentation and cold‑chain logistics where required.

Imigran (sumatriptan) acts on serotonergic pathways to provide rapid relief in migraine and related headache disorders.

Migraine (with or without aura): aborts acute migraine attacks, relieving headache pain and associated symptoms. Cluster headache: reduces pain intensity during an episodic cluster attack, offering rapid symptom control. Migraine with aura: alleviates visual and sensory disturbances accompanying the headache phase. Acute hemiplegic migraine: provides relief when other treatments are unsuitable.

Sumatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Chest discomfort or tightness: a transient feeling of pressure that usually resolves quickly. - Tingling or numbness in fingers or toes: paresthesia that is often mild and short‑lived. - Nausea or vomiting: gastrointestinal upset that may occur shortly after injection. - Injection site pain or erythema: mild pain, redness or swelling at the injection site.

Serious or Rare Side Effects: - Coronary vasospasm or myocardial infarction: reduced coronary blood flow that can lead to heart attack. - Severe hypertension or hypertensive crisis: sudden, marked increase in blood pressure requiring medical attention. - Serotonin syndrome, especially when combined with serotonergic agents: potentially life‑threatening condition with agitation, fever, and muscle rigidity.

Before using Imigran, healthcare professionals should evaluate patient history and follow specific safety measures. - Cardiovascular disease: avoid use in patients with coronary artery disease, angina, or history of myocardial infarction. - Uncontrolled hypertension: contraindicated in individuals with severe hypertension (>180/110 mmHg). - Hemiplegic or basilar migraine: not recommended due to increased risk of cerebrovascular events. - Concomitant serotonergic drugs: caution when used with SSRIs, SNRIs, or MAO inhibitors because of serotonin syndrome risk. - Pregnancy and lactation: safety not established; use only if potential benefit justifies potential risk. - Store at room temperature: keep in original packaging, protect from moisture and light, and do not freeze.

Sumatriptan can interact with several medication classes, affecting its safety and efficacy.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate severe serotonin syndrome. - Other triptans or ergot derivatives: combined use increases risk of vasospasm and cardiovascular events. - Serotonergic antidepressants (SSRIs, SNRIs, TCAs): may elevate serotonin levels leading to serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effects. - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): can increase sumatriptan plasma concentrations. - Oral contraceptives: may slightly raise risk of cardiovascular side effects.